NasdaqGS - Delayed Quote • USD
Bruker Corporation (BRKR)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 9 | 11 | 11 |
| Avg. Estimate | 0.46 | 0.57 | 2.73 | 3.41 |
| Low Estimate | 0.45 | 0.51 | 2.68 | 3.14 |
| High Estimate | 0.49 | 0.61 | 2.76 | 3.55 |
| Year Ago EPS | 0.64 | 0.5 | 2.68 | 2.73 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 9 | 10 | 10 |
| Avg. Estimate | 729.88M | 762.11M | 3.26B | 3.49B |
| Low Estimate | 717M | 749.64M | 3.25B | 3.44B |
| High Estimate | 742.11M | 775.42M | 3.29B | 3.6B |
| Year Ago Sales | 685.3M | 681.9M | 2.96B | 3.26B |
| Sales Growth (year/est) | 6.50% | 11.80% | 10.10% | 7.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.55 | 0.48 | 0.63 | 0.68 |
| EPS Actual | 0.64 | 0.5 | 0.74 | 0.8 |
| Difference | 0.09 | 0.02 | 0.11 | 0.12 |
| Surprise % | 16.40% | 4.20% | 17.50% | 17.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.46 | 0.57 | 2.73 | 3.41 |
| 7 Days Ago | 0.46 | 0.57 | 2.74 | 3.42 |
| 30 Days Ago | 0.46 | 0.57 | 2.74 | 3.44 |
| 60 Days Ago | 0.48 | 0.57 | 2.75 | 3.38 |
| 90 Days Ago | 0.61 | 0.6 | 2.77 | 3.15 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | BRKR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -28.10% | -- | -- | 0.80% |
| Next Qtr. | 14.00% | -- | -- | 9.60% |
| Current Year | 1.90% | -- | -- | 4.50% |
| Next Year | 24.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 14.15% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 18.36% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Goldman Sachs: Sell to Sell | 4/10/2024 |
| Maintains | UBS: Buy to Buy | 3/1/2024 |
| Maintains | UBS: Buy to Buy | 2/15/2024 |
| Maintains | Citigroup: Buy to Buy | 2/14/2024 |
| Maintains | Stifel: Hold to Hold | 2/14/2024 |
| Upgrade | JP Morgan: Neutral to Overweight | 2/14/2024 |
Related Tickers
UFPT UFP Technologies, Inc.
217.74
-3.50%
LIVN LivaNova PLC
52.76
+1.72%
AXNX Axonics, Inc.
67.05
-0.22%
CTKB Cytek Biosciences, Inc.
5.96
+0.68%
OFIX Orthofix Medical Inc.
13.02
+0.15%
ITGR Integer Holdings Corporation
117.83
-0.58%
GMED Globus Medical, Inc.
50.75
-0.88%
CNMD CONMED Corporation
71.08
-2.31%
IART Integra LifeSciences Holdings Corporation
31.63
-0.97%
STE STERIS plc
200.81
+0.28%